Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | ST6GAL1 | P15907 | 8/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109140 | 0.92 | P2RY2 (0.55) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL110081 | 0.92 | P2RY2 (0.58) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL112072 | 0.86 | P2RY2 (0.57) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL111695 | 0.85 | POLB (0.61) | P2RY2P2RY4P2RY6 | |
| SCHEMBL113175 | 0.84 | P2RY6 (0.62) | P2RY2P2RY4P2RY6 | |
| SCHEMBL4666825 | 0.82 | LMNA (0.62) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL12746220 | 0.81 | P2RY2 (0.67) | P2RY2TSHRGLALMNATHRB | |
| Cytarabine 5'-Phosphate SCHEMBL2681941 | 0.81 | P2RY2 (0.69) | P2RY2TSHRGLALMNATHRB | |
| Cytarabine 5'-Phosphate SCHEMBL17934719 | 0.81 | P2RY2 (0.69) | P2RY2TSHRGLALMNATHRB | |
| Cytarabine 5'-Phosphate SCHEMBL284602 | 0.81 | P2RY2 (0.69) | P2RY2TSHRGLALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | P2RY2 1050/4885TSHR 4502/4885GLA 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.